PMID- 15378520
OWN - NLM
STAT- MEDLINE
DCOM- 20050412
LR  - 20201215
IS  - 0270-4137 (Print)
IS  - 0270-4137 (Linking)
VI  - 63
IP  - 1
DP  - 2005 Apr 1
TI  - Immunological evaluation of individualized peptide vaccination with a low dose of 
      estramustine for HLA-A24+ HRPC patients.
PG  - 1-12
AB  - BACKGROUND: The safety, toxicity, and immunological response of individualized 
      peptide vaccination or human leukocyte antigen (HLA)-A24+ hormone refractory 
      prostate cancer (HRPC) patients in combination with a low dose of estramustine 
      were evaluated. METHODS: Sixteen patients with HLA-A24+ HRPC were enrolled in the 
      phase I/II study. Conducted immune monitorings for those patients were 
      peptide-specific cytotoxic T lymphocyte (CTL) precursor analysis by 
      interferon-gamma production and peptide-reactive immunoglobulin G (IgG) by an 
      enzyme-linked immunosorbent assay. Clinical responses and quality of life (QOL) 
      outcomes using a self-reported patient questionnaire were also evaluated. 
      RESULTS: Vaccinations were well tolerated, but all patients developed grade 1 or 
      2 local redness and swelling at the injection site. There was no significant 
      immunosuppression in most cases when the peptide and a half dose (280 mg/day) of 
      estramustine were administrated. Augmentation of peptide-specific CTL precursors 
      or peptide-specific IgG was observed in 10 of 14 or 7 of 14 patients at 12 weeks 
      (peptide vaccination alone), and in 6 of 8 or 10 of 12 patients at 24 weeks 
      (during the combination therapy), respectively. All 13 patients treated, with the 
      combination therapy, showed a decrease of serum prostate-specific antigen (PSA) 
      level from the baseline, including six patients with a serum PSA level decrease 
      of >or=50%. QOL outcomes were not deteriorated during the treatment. CONCLUSION: 
      These results might encourage the further evaluation of the combination of 
      peptide vaccination and a low dose of estramustine phosphate for HLA-A24+ HRPC 
      patients.
CI  - Copyright (c) 2004 Wiley-Liss, Inc.
FAU - Noguchi, Masanori
AU  - Noguchi M
AD  - Department of Urology, Kurume University, Kurume, Japan. 
      noguchi@med.kurume-u.ac.jp
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Yao, Akihisa
AU  - Yao A
FAU - Mine, Takashi
AU  - Mine T
FAU - Yamada, Akira
AU  - Yamada A
FAU - Obata, Yayoi
AU  - Obata Y
FAU - Furuta, Masatoshi
AU  - Furuta M
FAU - Harada, Mamoru
AU  - Harada M
FAU - Suekane, Shigetaka
AU  - Suekane S
FAU - Matsuoka, Kei
AU  - Matsuoka K
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Vaccines, Subunit)
RN  - 35LT29625A (Estramustine)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents, Alkylating/*administration & dosage
MH  - Combined Modality Therapy
MH  - Estramustine/*administration & dosage
MH  - Follow-Up Studies
MH  - HLA-A Antigens/*immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Immunotherapy
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/*drug therapy/mortality
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Vaccines, Subunit/*administration & dosage
EDAT- 2004/09/21 05:00
MHDA- 2005/04/13 09:00
CRDT- 2004/09/21 05:00
PHST- 2004/09/21 05:00 [pubmed]
PHST- 2005/04/13 09:00 [medline]
PHST- 2004/09/21 05:00 [entrez]
AID - 10.1002/pros.20157 [doi]
PST - ppublish
SO  - Prostate. 2005 Apr 1;63(1):1-12. doi: 10.1002/pros.20157.